-
公开(公告)号:US08455493B2
公开(公告)日:2013-06-04
申请号:US12632140
申请日:2009-12-07
申请人: Scott A. Mitchell , Kevin S. Currie , Peter A. Blomgren , Jeffrey E. Kropf , Seung H. Lee , Jianjun Xu , Douglas G. Stafford , James P. Harding , Antonio J. M. Barbosa, Jr. , Zhongdong Zhao , Soumya Mitra , David M. Armistead
发明人: Scott A. Mitchell , Kevin S. Currie , Peter A. Blomgren , Jeffrey E. Kropf , Seung H. Lee , Jianjun Xu , Douglas G. Stafford , James P. Harding , Antonio J. M. Barbosa, Jr. , Zhongdong Zhao , Soumya Mitra , David M. Armistead
IPC分类号: A61K31/495
CPC分类号: C07D487/04 , A61K31/495 , C07D471/04 , C07D491/107 , C07D498/04 , C07D519/00 , C12Q1/485 , G01N33/573 , G01N2333/91205
摘要: Certain imidazopyrazines of Formula (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
摘要翻译: 本文提供了式(I)的某些咪唑并嗪及其药物组合物。 治疗患有某些对抑制Syk活性有作用的疾病和病症的患者的方法,其包括给予这些患者一定量的至少一种有效减少疾病或病症体征或症状的化学实体。 还提供了用于确定样品中Syk激酶的存在或不存在的方法。
-
公开(公告)号:US08598174B2
公开(公告)日:2013-12-03
申请号:US13128726
申请日:2009-11-12
申请人: Antonio J. M. Barbosa, Jr. , Peter A. Blomgren , Kevin S. Currie , Seung Lee , Jeffrey E. Kropf , Scott A. Mitchell , Daniel Ortwine , William M. Rennells , Aaron C. Schmitt , Jianjun Xu , Wendy B. Young , Zhongdong Zhao , Pavel E. Zhichkin
发明人: Antonio J. M. Barbosa, Jr. , Peter A. Blomgren , Kevin S. Currie , Seung Lee , Jeffrey E. Kropf , Scott A. Mitchell , Daniel Ortwine , William M. Rennells , Aaron C. Schmitt , Jianjun Xu , Wendy B. Young , Zhongdong Zhao , Pavel E. Zhichkin
IPC分类号: A61K31/50 , A61K31/501 , C07D237/30
CPC分类号: C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D519/00
摘要: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
摘要翻译: 本文描述了抑制Btk的式I化合物。 描述了包含至少一种式I化合物的药物组合物以及选自载体,佐剂和赋形剂的至少一种药学上可接受的载体。 描述了治疗患有某些对Btk活性和/或B细胞活性的抑制作出反应的某些疾病的患者的方法。 描述了确定样品中Btk的存在的方法。
-
公开(公告)号:US07601714B2
公开(公告)日:2009-10-13
申请号:US11175476
申请日:2005-07-06
申请人: Antonio J. M. Barbosa, Jr. , Steven Richard Brunette , Eugene Richard Hickey , Jin Mi Kim , Michael David Lawlor , René Marc Lemieux , Bryan McKibben , Matt Aaron Tschantz , Hui Yu
发明人: Antonio J. M. Barbosa, Jr. , Steven Richard Brunette , Eugene Richard Hickey , Jin Mi Kim , Michael David Lawlor , René Marc Lemieux , Bryan McKibben , Matt Aaron Tschantz , Hui Yu
IPC分类号: C07D239/48 , C07D403/12 , A61K31/505
CPC分类号: C07D239/48 , C07D401/12 , C07D403/12
摘要: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
摘要翻译: 公开了式(I)的新化合物:其中X,Y,R 1,R 2和R 3如本文所定义,其可用作PKC-θ的抑制剂,因此可用于治疗介导的多种疾病和病症 通过PKC-θ的活性持续,包括免疫学障碍和II型糖尿病。 本发明还涉及包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和病症的方法,制备这些化合物的方法和可用于这些方法的中间体。
-
-